Biotech funding bill hits Senate

After linkurl:clearing;http://www.the-scientist.com/blog/display/54608/ the House of Representatives in April, a bill meant to extend the life of programs that stimulate innovation at linkurl:small biotech companies;http://www.the-scientist.com/blog/display/54816/ has finally found its way onto the floor of the Senate. The Senate Committee on Small Business and Entrepreneurship linkurl:passed the bill,;http://sbc.senate.gov/press/record.cfm?id=301536& which tacks on 14 years to the lifespans of

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
After linkurl:clearing;http://www.the-scientist.com/blog/display/54608/ the House of Representatives in April, a bill meant to extend the life of programs that stimulate innovation at linkurl:small biotech companies;http://www.the-scientist.com/blog/display/54816/ has finally found its way onto the floor of the Senate. The Senate Committee on Small Business and Entrepreneurship linkurl:passed the bill,;http://sbc.senate.gov/press/record.cfm?id=301536& which tacks on 14 years to the lifespans of both the Small Business Innovation Research (SBIR) and the Small Business Technology Transfer Research (STTR) programs, yesterday (July 30). Both programs, which aim to encourage the development and commercialization of products and technologies by small businesses, were due to sunset this September. The SBIR program granted more than $2 billion to start-ups last year. The bone of contention in the bill has been a clause stating that businesses where greater than 50 percent of stock is held by venture capital investors are still eligible for SBIR awards. The linkurl:Small Business Administration,;http://www.the-scientist.com/blog/display/54441/ which manages the programs through 11 federal agencies including the Department of Health and Human Services and the National Science Foundation, had resisted the provision. Current guidelines prohibit such companies from receiving SBIR grants. A compromise clause states that ten SBIR federal agencies can award up to 8 percent of their SBIR funds to these firms, and the National Institutes of Health can award up to 18 percent of its SBIR funds to such companies. Another compromise struck in the Senate committee involved the dollar amounts of SBIR grants. Where the linkurl:House version;http://thomas.loc.gov/cgi-bin/bdquery/z?d110:h.r.05819: indicated a raise in Phase I SBIR grants from $100,000 to $300,000 and a raise in Phase II grants from $750,000 to $2.2 million, the Senate committee's version scaled back those increases to $150,000 and $1 million for Phase I and II grants, respectively. The bill now goes before the full Senate and will return to the House so legislators there can review the changes.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo